TY  - JOUR
AU  - Isla, D
AU  - de Castro, J
AU  - García-Campelo, R
AU  - Lianes, P
AU  - Felip, E
AU  - Garrido, P
AU  - Paz-Ares, L
AU  - Trigo, J M
PY  - 2019
DO  - 10.1007/s12094-019-02191-y
UR  - http://hdl.handle.net/10668/14349
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression prompted us to...
LA  - en
KW  - Accumulated toxicity
KW  - Chemotherapy
KW  - Delphi consensus
KW  - Disease aggressiveness
KW  - Immunotherapy
KW  - Lung adenocarcinoma
KW  - Nintedanib
KW  - PD-L1 expression
KW  - Prior treatment
KW  - Progression-free interval
KW  - Treatment decisions
KW  - Tumour mutational burden
KW  - Adenocarcinoma of Lung
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B7-H1 Antigen
KW  - Clinical Decision-Making
KW  - Consensus
KW  - Delphi Technique
KW  - Disease Progression
KW  - Docetaxel
KW  - Humans
KW  - Immunotherapy
KW  - Indoles
KW  - Lung Neoplasms
KW  - Mutation
KW  - Spain
TI  - Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
TY  - research article
VL  - 22
ER  -